Dry Eye

Oculis announces positive data from phase 2 trials with novel topical TNF alpha antagonist OCS-02 for DED, acute anterior uveitis

May 11, 2021

Oculis reported positive data from two of its clinical proof-of-concept phase 2 trials for OCS-02, a novel topical anti-TNF alpha antibody fragment candidate, for the treatment of dry eye disease and acute anterior uveitis.

Repository corticotropin injections: Relief for refractory severe noninfectious keratitis

May 07, 2021

Joseph Grieco, PhD, notes that treatment fills a gap for patients who are unresponsive to the standard treatments for noninfectious keratitis.

Studying 10 years of dry eye disease flares

May 06, 2021

Christopher Starr, MD, discusses key points from his virtual ARVO 2021 presentation regarding dry eye disease flares, including a rapid readout assessment of 10 years' worth of world literature to analyze studies in which the inflammatory disease's condition are categorized.

Studying the relationship between dry eye symptoms and aging

May 01, 2021

Seth Miller, clinical operations manager at Ora Inc., discusses the relationship between the symptoms of dry eye and aging, based on his ARVO 2021 presentation.

Comparison of clinical outcomes of Schirmer's test with dry eye

May 01, 2021

Jeffrey Gemi, MD, Ora Inc., speaks on the highlights from his presentation comparing Schirmer's test with other clinical outcomes in dry eye.

Exploring the Management of Dry Eye

April 30, 2021

A panel of ophthalmologists and optometrists discuss the significance of addressing dry eye disease using various types of treatment strategies, including pharmacologic and non-pharmacologic options.

Company launches product targeting dry eye, MGD

April 20, 2021

ThermaMEDx has unveiled a self-heating, pre-moistened, disposable, sterile cleaning eye-pad for use in treating the symptoms of dry eyes and meibomian gland dysfunction.

Bausch + Lomb announces topline results for phase III trial of NOV03 to treat DED associated with MGD

April 13, 2021

Bausch + Lomb and Novaliq GmbH have announced statistically significant topline data from the first phase 3 trial analyzing the investigational drug NOV03 as a first-in-class eye drop to treat dry eye disease associated with MGD.

Treatment option for dry eye secondary to graft-vs-host disease

March 25, 2021

Product offers improvement in objective dry eye disease measures, providing relief.

Minocycline shows promise in dry eye trial

March 19, 2021

Phase 2 trial of 0.3% minocycline microparticle suspension shows promise in dry eye diseases associated with Inflamed meibomian gland dysfunction